awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFC
Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFC
Analysis of the efficacy and safety of a combined gemcitabine, oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma
P2860
Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFC
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37376566-DD863A48-8A01-4575-A0B9-863252F15DFC
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0e5b968c94d859c057a1484c61006a7e1acc2755
P2860
FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).